Antihyperalgesic and allodynic effect of granisetron-A P1 receptor agonist in vincristine induced neuropathy in mice

Objective: Granisetron, GRA an adenosine receptor agonist with fewer side effects, could be of interest to reduce neuropathic pain following antineoplasic drug treatment. In the present study, we demonstrated that Granisetron inhibits hyperalgesia and allodynia in a new mice model of neuropathy induced by Vincristine, and exerts its effect preferentially via supraspinal and spinal mechanisms. Method: Mice pretreated with Vincristine sulphate (100 μg/kg, i.v) showed induction of neuropathic pain was administered with Granisetron (1 and 10mg/kg. i.p.) for five days. Neuropathic pain symptoms like hyperalgesia and allodynia (mechanical) were evaluated in all the group of animals and reduction in neuropathic pain in drug treated group was compared on 5 day with vehicle treated control group in order to confirm the effectiveness of drug against the symptoms. Key findings: P 1 receptor agonist Granisetron at the dose level of 1 and 10mg/kg.i.p. was found to be significantly effective (P<0.05) against neuropathic pain. Conclusion: These results suggest that P 1 receptor agonist Granisetron at the dose range used may provide a better insight in the development of the newer drug for neuropathic pain.